Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial

The Lancet Infectious Diseases

Volumn 17, Issue 5, 2017, Pages 498-509

  Sissoko, Mahamadou S ^a   Healy, Sara A ^b   Katile, Abdoulaye ^a   Omaswa, Freda ^c   Zaidi, Irfan ^b   Gabriel, Erin E ^b   Kamate, Bourama ^a   Samake, Yacouba ^a   Guindo, Merepen A ^a   Dolo, Amagana ^a   Niangaly, Amadou ^a   Niaré, Karamoko ^a   Zeguime, Amatigue ^a   Sissoko, Kourane ^a   Diallo, Hama ^a   Thera, Ismaila ^a   Ding, Kelly ^b   Fay, Michael P ^b   O'Connell, Elise M ^b   Nutman, Thomas B ^b   Wong Madden, Sharon ^b   Murshedkar, Tooba ^c   Ruben, Adam J ^c   Li, Minglin ^c   Abebe, Yonas ^c   Manoj, Anita ^c   Gunasekera, Anusha ^c   Chakravarty, Sumana ^c   Sim, B Kim Lee ^c   Billingsley, Peter F ^c   James, Eric R ^c   Walther, Michael ^b   Richie, Thomas L ^c   Hoffman, Stephen L ^c   Doumbo, Ogobara ^a   Duffy, Patrick E ^b   more..

^a Sociétés   (Mali)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c SANARIA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; MALARIA VACCINE; PLACEBO; PLASMODIUM FALCIPARUM SPOROZITE VACCINE; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMISININ DERIVATIVE; BENFLUMETOL; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE;

ADULT; ANTIBODY RESPONSE; ARTICLE; BLOOD SMEAR; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ELIMINATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INOCULATION; MAJOR CLINICAL STUDY; MALARIA; MALARIA FALCIPARUM; MALE; MALI; NONHUMAN; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VACCINATION; ADOLESCENT; CLINICAL TRIAL; IMMUNIZATION; IMMUNOLOGY; MALARIA, FALCIPARUM; PROCEDURES;

ADOLESCENT; ADULT; ANTIMALARIALS; ARTEMISININS; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; IMMUNIZATION SCHEDULE; MALARIA, FALCIPARUM; MALE; MALI; PLASMODIUM FALCIPARUM; VACCINATION;

EID: 85012938740     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30104-4     Document Type: Article

References (30)

1. 1 WHO. World malaria report, 2015, World Health Organization, Geneva.
2. 2 Clyde, DF, Most, H, McCarthy, VC, Vanderberg, JP, Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci 266 (1973), 169–177.
3. 3 Rieckmann, KH, Beaudoin, RL, Cassells, JS, Sell, KW, Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bull World Health Organ 57:suppl 1 (1979), 261–265.
4. 4 Hoffman, SL, Goh, LM, Luke, TC, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 185 (2002), 1155–1164.
5. 5 Roestenberg, M, McCall, M, Hopman, J, et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 361 (2009), 468–477.
6. 6 Hoffman, SL, Billingsley, PF, James, E, et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin 6 (2010), 97–106.
7. + T cell immunity. Science 334 (2011), 475–480.
8. 8 Seder, RA, Chang, LJ, Enama, ME, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341 (2013), 1359–1365.
9. 9 Ishizuka, AS, Lyke, KE, DeZure, A, et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med 22 (2016), 614–623.
10. 10 Epstein, JE, Paolino, KM, Richie, TL, et al. Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. JCI Insight, 2, 2017, e89154.
11. 11 Dicko, A, Sagara, I, Diemert, D, et al. Year-to-year variation in the age-specific incidence of clinical malaria in two potential vaccine testing sites in Mali with different levels of malaria transmission intensity. Am J Trop Med Hyg 77 (2007), 1028–1033.
12. 12 Diallo, DA, Doumbo, OK, Plowe, CV, Wellems, TE, Emanuel, EJ, Hurst, SA, Community permission for medical research in developing countries. Clin Infect Dis 41 (2005), 255–259.
13. 13 US Food and Drug Administration. Guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074775.htm, 2007 (accessed Jan 27, 2017).
14. 14 Easton, AV, Oliveira, RG, O'Connell, EM, et al. Multi-parallel qPCR provides increased sensitivity and diagnostic breadth for gastrointestinal parasites of humans: field-based inferences on the impact of mass deworming. Parasit Vectors, 9, 2016, 38.
15. 15 Fay, MP, Shaw, PA, Exact and asymptotic weighted logrank tests for interval censored data: the interval R package. J Stat Softw, 36, 2010, i02.
16. 16 Fay, MP, Proschan, MA, Brittain, E, Combining one-sample confidence procedures for inference in the two-sample case. Biometrics 71 (2015), 146–156.
17. 17 Richie, TL, Billingsley, PF, Sim, BK, et al. Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine 33 (2015), 7452–7461.
18. 18 Ogwang, C, Kimani, D, Edwards, NJ, et al. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Sci Transl Med, 7, 2015, 286re5.
19. 19 Bojang, KA, Milligan, PJ, Pinder, M, et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358 (2001), 1927–1934.
20. 20 Polhemus, ME, Remich, SA, Ogutu, BR, et al. Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS One, 4, 2009, e6465.
21. 21 Bojang, K, Milligan, P, Pinder, M, et al. Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia. Hum Vaccin 5 (2009), 242–247.
22. 22 Hoffman, SL, Vekemans, J, Richie, TL, Duffy, PE, The march toward malaria vaccines. Am J Prev Med 49:6 suppl 4 (2015), S319–S333.
23. 23 Elias, D, Wolday, D, Akuffo, H, Petros, B, Bronner, U, Britton, S, Effect of deworming on human T cell responses to mycobacterial antigens in helminth-exposed individuals before and after bacille Calmette-Guerin (BCG) vaccination. Clin Exp Immunol 123 (2001), 219–225.
24. 24 Borkow, G, Bentwich, Z, Chronic parasite infections cause immune changes that could affect successful vaccination. Trends Parasitol 24 (2008), 243–245.
25. 25 Harty, JT, Badovinac, VP, Shaping and reshaping CD8+ T-cell memory. Nat Rev Immunol 8 (2008), 107–119.
26. 26 Kaech, SM, Wherry, EJ, Ahmed, R, Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2 (2002), 251–262.
27. 27 Struik, SS, Riley, EM, Does malaria suffer from lack of memory?. Immunol Rev 201 (2004), 268–290.
28. + T cells and antibodies required for immunity to malaria sporozoites. Nature 330 (1987), 664–666.
29. 29 Weiss, WR, Jiang, CG, Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites. PLoS One, 7, 2012, e31247.
30. 30 Garcia, CR, Manzi, F, Tediosi, F, Hoffman, SL, James, ER, Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine. Vaccine 31 (2013), 380–386.